Form 4: LifeCore Biomedical Executive Acquires Shares Following RSU Vesting on Stock Price Milestone

LifeCore Biomedical's Chief Legal & Administration Officer, Thomas D. Salus, acquired 37,000 shares of common stock through the vesting of performance-based restricted stock units, with a portion withheld for tax obligations.

Summary

• Thomas D. Salus, Chief Legal & Administration Officer of LIFECORE BIOMEDICAL, INC., acquired 37,000 shares of common stock on July 8, 2025.
• These shares were acquired through the vesting of performance-based restricted stock units.
• The vesting was triggered by the Issuer's achievement of a specific stock price milestone.
• Concurrently, 11,022 shares were disposed of at a price of $8.19 per share to cover applicable tax withholding obligations related to the vesting.
• Following these transactions, Thomas D. Salus directly beneficially owns 240,978 shares of common stock and 333,000 performance-based restricted stock units.

Sentiment

Score: 7

Explanation: The vesting of performance-based restricted stock units due to achieving a stock price milestone is a positive indicator of company performance and aligns executive incentives with shareholder value, despite the routine sale of shares for tax purposes.

Positives

• The vesting of performance-based restricted stock units indicates the company achieved a stock price milestone, suggesting positive performance.
• The acquisition of 37,000 shares by a key executive increases their direct ownership in the company, aligning interests with shareholders.

Negatives

• 11,022 shares were sold to cover tax withholding obligations, which is a common practice but reduces the net shares acquired.

Future Outlook

NA

Industry Context

This transaction reflects standard executive compensation practices tied to performance milestones within the biotechnology or pharmaceutical industry, where stock-based incentives are common to align management interests with shareholder value.

Comparison to Industry Standards

• The use of performance-based restricted stock units (RSUs) is a common executive compensation mechanism across various industries, including biotech and healthcare, aligning executive incentives with company performance and shareholder returns.
• The practice of withholding shares to cover tax obligations upon RSU vesting is standard industry practice, ensuring compliance with tax laws without requiring executives to make out-of-pocket payments for taxes.
• The achievement of a stock price milestone for RSU vesting is a typical performance metric in such plans, comparable to similar incentive structures seen in companies like Amgen or Gilead Sciences, which often tie executive bonuses and equity awards to specific financial or operational targets.

Related Party Transactions

• The transaction involves the acquisition of shares by a Chief Legal & Administration Officer, Thomas D. Salus, from the issuer, LIFECORE BIOMEDICAL, INC., which is a direct related-party transaction as per SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders: The vesting of performance-based units due to a stock price milestone could be viewed positively, indicating the company is meeting its performance targets, which may instill confidence. The executive's increased direct ownership aligns their interests with shareholders.
• Management/Employees: The vesting and acquisition of shares by a key executive demonstrates the effectiveness of the company's incentive compensation plans and rewards for achieving strategic goals.

Key Dates

Recommendation

Keywords

LIFECORE BIOMEDICAL, LFCR, Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, RSU Vesting, Executive Compensation, Thomas D. Salus, Stock Price Milestone, Tax Withholding